CD40LG and Sepsis: In light of the protective effect of pIgR_Ab in both KPS and CLP sepsis models, pIgR-neutralizing antibodies targeting the binding site(s) of IgM and dIgA may have the potential for the treatment of sepsis that claims approximately 11 million human lives annually worldwide (16).